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The measurement of CA50 in serum and pleural fluid by immunoradiometric assay was presented in 45 (27 
malignancy and 18 tuberculosis) patients with pleural effusion. The mean CA50 level in malignant effusion 
(89.26 f 122.32 U ml-‘) was significantly higher than that in tuberculous effusion (5.18 + 8.65 U ml-‘) 
(P< 0.001). CA50 levels of pleural fluid above an arbitrary level of 20 U ml-’ were found in 78% of malignant 
fluids and in 6% of tuberculous fluids. The serum CA50 value from 27 patients with malignant effusion 
(58.67 f 85.85 U ml-‘) was also higher than that from 18 patients with tuberculous effusion (6.18 &- 8.37 U ml-‘) 
(P< 0.001). CA50 levels of serum above the same level were found in 58% of patients with malignant fluid and in 
6% of patients with tuberculous fluid. The results suggested that the measurement of CA50 in pleural effusion 
may be helpful in the differential diagnosis between tuberculous and malignant effusions. 
Introduction 
CA50 is a newly characterized carcinoma associated 
antigen. Raised CA50 levels in fluids and tumour 
tissues of patients with different types of epithelial 
tumour have been reported (14). It may be useful in 
clinical research studies of the diagnosis, management 
and prognosis of patients with different types of carci- 
noma. This paper reports the measurement of CA50 
in serum and pleural fluid in patients with malignant 
and tuberculous effusions by immunoradiometric 
assay (IRMA) with monoclonal antibody. We have 
attempted to establish the diagnostic values of 
CA50 to differentiate malignant from nonmalignant 
effusion. 
Patients and Methods 
PATIENTS 
Twenty-seven patients were found after investi- 
gation to have malignant effusions, including 12 with 
lung adenocarcinomas, seven with lung epidermoid 
carcinomas, two with lung small cell anaplastic carci- 
nomas, and two with breast cancer. In four of them, a 
cell type was not demonstrated. 
Eighteen patients had benign effusion, all due to 
tuberculosis. 
SAMPLES 
Fluid samples were obtained by needle puncture. 
After centrifugation, the supernatants were stored at 
- 20°C. 
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Blood was obtained by venipuncture. Blood was 
separated from clotted blood by centrifugation. Serum 
samples were stored at - 20°C. 
ASSAYS 
A sandwich model of IRMA with ‘251-labelled 
monoclonal antibody C50 and CSO-coated poly- 
styrene beads was designed for determination of CA50 
antigen (5). C50 monoclonal antibody (MAb), poly- 
styrene beads coated with CA50 antigen and standard 
CASO-antigen-positive serum were purchased from 
Stena AB, Sweden. Polystyrene beads (6.4 mm, Beijing 
Button Factory, Beijing, China) were coated with C50 
MAb by incubation with C50 MAb in bicarbonate 
buffered saline, pH 9.6, 0.05 mol 1-l. The tracer C50 
MAb was labelled to a specific radioactivity using 
Greenwood’s method (6). 
Assay procedure 
A 50 ~1 sample or standard were mixed with 100 ~1 
1251-labelled MAb C50 and 50~1 assay buffer in test 
tubes. A polystyrene bead coated with C50 was then 
added to each tube. After the mixture, they were 
incubated overnight at 4°C. The next morning, the 
liquid was removed by aspiration and the beads were 
washed three times with distilled water. The radio- 
activity of the beads was determined with a gamma 
counter. 
The coefficient of variation between repeat tests for 
the same specimen on different occasions was 7%. 
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Fig. I CA50 levels of serum in patients with tuberculous and 
malignant effusions. 
STATISTICAL ANALYSIS 
Groups were compared according to Student’s 
r-test. 
Results 
CA50 IN SERUM 
CA50 levels of serum in patients with malignant 
effusion were 58.67f 85.85 U ml-’ significantly higher 
than in patients with tuberculous effusion (6.18+ 
8.37 U ml-‘). According to Fig. 1, CA50 levels above 
20Uml-’ were found in 16 of 27 patients with 
malignant effusion (58%) and in 1 of 18 patients with 
tuberculous effusion (6%). The specificity was 94%, 
the positive predictive value 94%. 
CA50 IN PLEURAL FLUID 
CA50 levels in malignant fluids were 89.26* 
122.32 U ml-’ significantly higher than in tuberculous 
fluids (5.18k8.65 U ml-‘) (P<O.OOl). According to 
Fig. 2, CA50 levels above 20 U ml-’ were found in 21 
of 27 malignant fluids (78%) and in one of 18 tubercu- 
lous fluids (6%). The specificity was 94%, the positive 
predictive value 95%. 
There was not significant difference between the 
CA50 levels of serum and effusion in patients with 
tuberculous effusion (P>O.O5). The CA50 level of 
effusion was higher than that of serum in patients with 
malignant effusion (PC 0.01). The CA50 values of 
serum were higher than those of effusion in two 
patients with malignant effusion who had diffuse 
metastasis. This may be due to a great deal of CA50 
synthesized and secreted by metastatic tumour tissues 
in the whole body. 
Discussion 
The reason for raised CA50 levels in fluids and 
tumour tissues of patients with carcinoma is not 
completely clear. CA50 may occur both as a glycolipid 
and as a sialylated glycoprotein (1). They, especially 
glycolipids, are the major components of cell mem- 
brane receptors and relate to regulating cell functions. 
When a cell is malignant, the changes of glycolipid 
composition of cell membrane are due to suppressed 
glycosyl transferase or activation of an unusual 
enzyme with less restricted substrate specificity (7). 
Raised CA50 levels in fluids and tumour tissues of 
patients with cancer may also be due to these changes. 
In 1984 Holmgren determined the value of CA50 in 
the serum of patients with different types of carcinoma 
by means of IRMA. Serum values of CA50 exceeding 
the mean plus three standard deviations for control 
samples from blood donors were found in the high 
proportion of patients with colorectal adenocarcino- 
mas (50% of those with early localized tumours and 
75% of advanced cases), other gastrointestinal carci- 
nomas (69%) uterine cancer (75%) prostatic cancer 
(90%), lung cancer (52%) other cancer (26661%). 
The CA50 values in samples from patients with in- 
flammatory diseases, including ulcerative colitis and 
pneumonia, with rare exceptions (O-7%) were within 
the normal range (I). Therefore CA50 is regarded as 
a tumoral marker and it may be useful in clinical 
research studies of the diagnosis of patients with 
different types of carcinoma. 
Our study shows that CA50 pleural fluid for diag- 
nosing malignant effusion has excellent specificity 
and predictive value and a moderately high sensitivity. 
Six patients with malignant effusion showing false 
negative included one with lung adenocarcinomas, one 
with small cell carcinomas, one with lung epidermoid 
carcinomas, two with breast cancer and two with 
malignant effusion of unknown cell type. The false 
negative rate of lung cancer was only 14%, lung adeno- 
carcinomas 8%. This shows the positive rate of CA50 
is related to histopathological types of carcinoma. 
The cause of a pleural effusion is a common 
clinical problem. Using both routine and specialized 
investigations, we have found approximately 20% of 
effusions to be diagnostic problem, especially dis- 
crimination between malignant and benign effusions. 
IRMA is a specific, convenient method of measuring 
CA50. This assay may be a useful tool for diagnosing 
malignant effusion. The combination of CA50, cyto- 
logical examinations and other tumoral markers in 
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Fig. 2 CA50 levels in tuberculous and malignant effusions. 
pleural fluid will be helpful to discriminate between 
malignant and tuberculous effusions. 
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